BridgeBio to present late-breaking infigratinib data at ESPE 2026
BridgeBio Pharma said it will present one late-breaking oral presentation on the impact of oral infigratinib on medical complications in achondroplasia at the Annual ESPE Meeting 2026.
PALO ALTO, Calif., Sept.
02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc.
NASDAQ:BBIO (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that one late-breaking oral presentation on th…